Sponsor Check › Person
Related person on Form D filings · address states as listed: MA, MD, NC, CA, PA · listed Jun 21, 2010 → Feb 9, 2017
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 23, 2026, 11:58 PM ET · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
None found in sources searched.
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 23, 2026, 11:58 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
None found in sources searched.
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 23, 2026, 11:58 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
0 of 17 offerings report sales commissions; 1 reports finder's fees totalling $720,000; 3 report proceeds to related persons totalling $4,250,000. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Feb 9, 2017 D/A File 021-256322 | $0 | $720,000 (est.) | $2,500,000 (est.) | MTS Securities, LLC BrokerCheck CRD 104059 ↗ |
| EDGAR ↗ | Feb 9, 2017 D File 021-280364 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 31, 2017 D File 021-279697 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 28, 2016 D File 021-275193 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 14, 2015 D File 021-249325 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 21, 2015 D/A File 021-235733 | $0 | $0 | $900,000 (est.) | None listed on this filing |
| EDGAR ↗ | Feb 13, 2015 D File 021-234073 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 6, 2014 D File 021-222406 | $0 | $0 | $850,000 The amount listed above represents estimated compensation due to the company's executive officers. | None listed on this filing |
| EDGAR ↗ | Jul 25, 2014 D File 021-221750 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 12, 2014 D File 021-213366 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 24, 2013 D/A File 021-188774 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 20, 2013 D File 021-203196 | $0 | $0 | $0 None, other than compensation in the ordinary course of business. | None listed on this filing |
| EDGAR ↗ | Nov 7, 2012 D File 021-186614 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 18, 2012 D/A File 021-40668 | $0 | $0 | $0 Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering. | None listed on this filing |
| EDGAR ↗ | Sep 2, 2011 D File 021-165360 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 30, 2010 D File 021-145689 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 21, 2010 D File 021-143788 | $0 | $0 | $0 Not including salaries and bonuses paid to executive officers in the ordinary course of business. | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | Tarveda Therapeutics, Inc. | Director | Feb 9, 2017 | D | $30,000,001 similar: $2,000,000–$19,999,994 | $30,000,001 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Tarveda Therapeutics, Inc. | Director | Feb 9, 2017 | D/A | $38,000,000 similar: $2,000,000–$19,999,994 | $38,000,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | PhaseBio Pharmaceuticals Inc | Director | Jan 31, 2017 | D | $7,875,000 similar: $2,000,000–$19,999,994 | $6,615,000 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Galera Therapeutics, Inc. | Director | Nov 28, 2016 | D | $15,000,000 similar: $1,694,259–$16,000,000 | $15,000,000 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Tarveda Therapeutics, Inc. | Director | Jan 29, 2016 | D | $38,000,000 similar: $2,000,000–$19,999,994 | $25,519,178 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Galera Therapeutics, Inc. | Director | Oct 14, 2015 | D | $37,102,500 similar: $1,694,259–$16,000,000 | $37,102,500 | 7 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | PhaseBio Pharmaceuticals Inc | Director | Jul 21, 2015 | D/A | $42,000,000 similar: $2,000,000–$19,999,994 | $21,000,000 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | PhaseBio Pharmaceuticals Inc | Director | Mar 12, 2015 | D | $40,000,000 similar: $2,000,000–$19,999,994 | $20,000,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | NexImmune, Inc. | Director | Feb 13, 2015 | D | $1,962,000 similar: $2,000,000–$19,999,994 | $1,962,000 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Galera Therapeutics, Inc. | Director | Aug 6, 2014 | D | $9,480,000 similar: $2,000,000–$19,999,994 | $4,740,000 | 7 similar: 2–16 | $25,000 similar: $10,000–$50,000 |
| EDGAR ↗ | NexImmune, Inc. | Director | Jul 25, 2014 | D | $3,000,000 similar: $2,000,000–$19,999,994 | $3,000,000 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Tarveda Therapeutics, Inc. | Director | Mar 12, 2014 | D | $999,999 similar: $2,000,000–$19,999,994 | $999,999 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Tarveda Therapeutics, Inc. | Director | Dec 24, 2013 | D/A | $21,001,168 similar: $2,000,000–$19,999,994 | $21,001,164 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Zosano Pharma Corp group: Zosano Pharma | Director | Sep 20, 2013 | D | $3,033,723 | $3,033,723 | 5 | No minimum reported |
| EDGAR ↗ | Tarveda Therapeutics, Inc. | Director | Dec 20, 2012 | D | $21,001,168 | $16,001,168 | 8 | No minimum reported |
| EDGAR ↗ | CARDIOXYL PHARMACEUTICALS INC | Director | Nov 7, 2012 | D | $28,050,000 | $28,050,000 | 5 | No minimum reported |
| EDGAR ↗ | PhaseBio Pharmaceuticals Inc | Director | Jun 18, 2012 | D/A | $48,524,067 | $48,524,067 | 17 | No minimum reported |
| EDGAR ↗ | Tarveda Therapeutics, Inc. | Director | Sep 2, 2011 | D | $2,800,000 | $2,800,000 | 3 | No minimum reported |
| EDGAR ↗ | PhaseBio Pharmaceuticals Inc | Director | Dec 6, 2010 | D/A | $25,300,001 | $25,300,001 | 12 | No minimum reported |
| EDGAR ↗ | CARDIOXYL PHARMACEUTICALS INC | Director | Jul 30, 2010 | D | $15,000,000 | $15,000,000 | 2 | No minimum reported |
| EDGAR ↗ | PREDICTIVE BIOSCIENCES, INC | Director | Jun 21, 2010 | D | $25,368,777 | $25,368,777 | 10 | No minimum reported |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Separate person records under the same name, not combined with this page. Each line says whether it is listed on an issuer this record is also listed on (a second identifier); where it is not, it could be the same person or a different one.
People and management entities the issuers listed as related persons on the same Form D filings as James Barrett. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when James Barrett appears on a new Form D, or when a court case or SEC action is matched to them. See plans →